This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Diabetes Mellitus  • Congestive Heart Failure/ Cardiomyopathy  • Adverse Effects  • Alert me on articles by topic

Nasser Mikhail, MD, MSc

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the trial by Hollander et al,¹ the excess rates of cardiovascular (CV) events with rosiglitazone use (2.4% in the 2-mg/d group and 1.4% in the 4-mg/d group vs 0.9% in the placebo group) are of concern because of several reasons. First, these events occurred with rosiglitazone doses as low as 2 mg/d and after short-time exposure to the drug (within 24 weeks). Second, they were in agreement with the overall results of a meta-analysis² of 42 trials showing that rosiglitazone use was associated with a significant risk of myocardial infarction (odds ratio, 1.43; 95% confidence interval, 1.03-1.98 [P = .03]). The meta-analysis² included the trial by Hollander et al¹ before its publication and peer review, when it was reported in a summary fashion on the Web site of the drug manufacturer. Although the interim data of the randomized RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Low-Dose Rosiglitazone in Patients With Insulin-Requiring Type 2 Diabetes
Priscilla Hollander, Dahong Yu, and Hubert S. Chou
Arch Intern Med. 2007;167(12):1284-1290.
ABSTRACT | FULL TEXT